ZYMEHealthcare · BiotechnologyThe 13 Wall Street analysts covering Zymeworks, Inc. hold a median 12-month price target of $39 — +53.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Zymeworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (95): The share price has been relatively steady.
Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ZYME, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +53.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | $40 → $44 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $31 → $32 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $37 → $40 |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $46 → $51 |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 7 July 2026 | Truist Securities | Maintains | Buy | $28 → $31 |
| 30 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 June 2026 | Wells Fargo | Maintains | Overweight | $34 → $37 |
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Mar 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2026 | Leerink Partners | Maintains | Outperform | — |
| 3 Mar 2026 | Stifel | Maintains | Buy | — |
| 17 Dec 2025 | Truist Securities | Initiates | Buy | — |
| 12 Dec 2025 | Wells Fargo | Upgrade | Overweight | — |
| 3 Dec 2025 | Citizens | Initiates | Market Outperform | — |
| 21 Nov 2025 | B. Riley Securities | Reiterates | Buy | — |
| 19 Nov 2025 | Stifel | Maintains | Buy | — |
| 19 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZYME appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 6% of US stocks
Cheaper than 9% of US stocks
Cheaper than 84% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zymeworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Theravance Biopharma reported second-quarter earnings that matched estimates. Following the discontinuation of ampreloxetine, the company implemented cost cuts and is set to be acquired by Zymeworks in a $929 million deal.
Why it matters — A Zymeworks watcher would care because this acquisition expands Zymeworks' scope and represents a significant corporate development for the company.
Zymeworks reported a Q2 loss of $0.62 per share, wider than the Zacks Consensus Estimate of a $0.56 loss and versus earnings of $0.03 per share in the same quarter a year ago, while revenue beat estimates.
Why it matters — The results show a year-over-year swing from profit to a loss that was larger than analysts expected, which is directly relevant to ZYME watchers tracking quarterly performance.
Zymeworks reported its second quarter 2026 financial results and corporate update, highlighting a U.S. PDUFA target action date for zanidatamab that could trigger a $250 million U.S. approval milestone and up to $190 million in additional global regulatory milestones. The company also expects its acquisition of Theravance Biopharma to close in the second half of 2026, advanced its R&D pipeline, repurchased $49.4 million of common shares, and held $322.5 million in cash and securities as of June 30, 2026.
Why it matters — The update signals key near-term catalysts—zanidatamab's U.S. approval milestone and the Theravance acquisition adding commercial cash flows—alongside a strong cash position and an active share repurchase program.
The 13 Wall Street analysts covering Zymeworks, Inc. have a median 12-month price target of $39, with estimates ranging from $31 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Zymeworks, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zymeworks, Inc. 70 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Zymeworks, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +53.3% from the last close, and Ticker Nerd's factor model ranks Zymeworks, Inc. 70 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zymeworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $58 over the next 12 months.
Zymeworks, Inc. returned +75.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Zymeworks Inc. is a biotechnology company that focuses on innovating biotherapeutics for the treatment of cancer and autoimmune diseases.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks". Theravance Biopharma reported second-quarter earnings that matched estimates. Following the discontinuation of ampreloxetine, the company implemented cost cuts and is set to be acquired by Zymeworks in a $929 million deal.
Zymeworks Inc. is a biotechnology company that focuses on innovating biotherapeutics for the treatment of cancer and autoimmune diseases. The company's core mission revolves around developing novel, multifunctional therapeutics with the potential to improve efficacy and reduce side effects compared to conventional cancer treatments. Zymeworks utilizes its proprietary platforms, such as the Azymetric and EFECT technologies, which enable the creation of multifunctional antibody therapeutics. These assets are significant in sectors such as oncology and immunology, addressing unmet needs with therapies aimed at complex and difficult-to-treat conditions. Based in Canada, Zymeworks collaborates with leading global pharmaceutical companies to enhance the reach and impact of its research. In the financial market, Zymeworks Inc. is notable for its strategic partnerships and potential for contributing to advancements in precision medicine, emphasizing its role not only in scientific innovation but also as a key player in the biotech industry's approach to personalized healthcare solutions.
CEO Mr. Kenneth H. Galbraith C.A. · 231 employees · United States · https://www.zymeworks.com